gel vehicle-Curatek Pharmaceuticals, LLC-bacterial vaginosis

The gel vehicle-Curatek Pharmaceuticals, LLC-bacterial vaginosis refers to the placebo control formulation used in clinical trials for MetroGel-Vaginal (metronidazole vaginal gel, 0.75%). Developed by Curatek Pharmaceuticals, this vehicle is a non-medicated gel that contains the same inactive ingredients as the active drug product but lacks the antimicrobial agent metronidazole. It was specifically designed for use in Phase 3 randomized, double-blind, placebo-controlled studies to establish a baseline for safety and efficacy in the treatment of bacterial vaginosis. The vehicle is applied intravaginally, typically once daily for 5 days, to match the administration regimen of the active treatment, ensuring that the study results accurately reflect the therapeutic benefit of the active antibiotic over the formulation base alone.

Other names

MetroGel-Vaginal vehiclevaginal gel vehicle